4baseCare, a leading innovator in precision oncology, has developed world’s first Indian population specific cancer gene panel tailored specifically for the Indian population.
Founded by Hitesh Goswami and Kshitij Rishi, 4baseCare is at the forefront of integrating advanced genomic solutions and digital technologies to revolutionize cancer care across Asia.
Cancer treatment traditionally follows a one-size-fits-all approach, which often fails to account for the unique genetic makeup of individual tumors.
This has led to suboptimal outcomes and the pressing need for a more personalized approach.
Precision oncology addresses this challenge by leveraging genomic information to tailor treatments based on the specific genetic profile of a patient’s cancer.
4baseCare’s latest innovation, the TARGT Indiegene panel, represents a breakthrough in this field.
This gene panel is one of the largest of its kind globally, developed through comprehensive profiling of the whole exome and transcriptome.
By focusing on the genetic uniqueness of the Indian population, the panel aims to provide more accurate and effective treatment options for patients, enhancing both the efficacy of therapies and overall patient outcomes.
As part of its commitment to advancing precision oncology, 4baseCare is also known for its comprehensive genomic profiling (CGP) services.
These services use Next Generation Sequencing (NGS) to analyze both somatic and germline variants, providing oncologists with critical insights to guide personalized treatment decisions.
The company’s TARGT portfolio includes tests that identify actionable genetic mutations associated with approved treatments and clinical trials, including single nucleotide variants (SNVs), insertions/deletions (Indels), copy number alterations (CNAs), and genomic signatures like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
4baseCare’s dedication to enhancing cancer care extends beyond genomic profiling.
The company’s digital healthcare platform, OncoBuddy, offers a holistic support system for patients throughout their cancer journey.
OncoBuddy connects patients with medical professionals, provides educational resources, and offers tools for managing personal health records through its OncoPHR feature.
Additionally, OncoBuddy facilitates virtual consultations via OncoConsult, allowing patients to access expert care from the comfort of their homes.
By combining advanced genomic solutions with cutting-edge digital technology, 4baseCare aims to make personalized cancer care more accessible and effective.
The TARGT Indiegene panel, in particular, marks a significant step towards addressing the genetic diversity of cancer within the Indian population, paving the way for more targeted and successful treatment strategies.
4baseCare’s mission is clear: to give cancer patients the best chance at fighting their disease.
By integrating state-of-the-art genomic testing with supportive digital tools, the company is not only advancing the field of precision oncology but also transforming the landscape of cancer care in Asia.
As 4baseCare continues to innovate and expand its services, its founders’ vision of individualized, effective cancer treatment becomes increasingly attainable, offering new hope and improved outcomes for patients across the continent.
